SCHEMBL6442525

SCHEMBL6442525

CSc1nc(N)nc(-n2cccn2)c1C#N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.56
CYP1A2 P05177 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP3A4 P08684 1/20 0.45
ALDH1A1 P00352 9/20 0.44
MAPT P10636 8/20 0.44
MEN1 O00255 8/20 0.44
KMT2A Q03164 8/20 0.44
HSD17B10 Q99714 3/20 0.44
CASP1 P29466 2/20 0.44
CASP7 P55210 2/20 0.44
RXFP1 Q9HBX9 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 1/20 0.40
HPGD P15428 4/20 0.40
LMNA P02545 5/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KDM4E B2RXH2 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6440583 0.77 CYP1A2 (0.41) CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1
SCHEMBL6444478 0.77 MEN1 (0.43) CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1
SCHEMBL6443544 0.77 CYP1A2 (0.44) ADORA2ACYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL6446101 0.76 ALDH1A1 (0.44) CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1
SCHEMBL6441931 0.76 RXFP1 (0.41) CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1
SCHEMBL6445313 0.76 ADORA2A (0.53) ADORA2AADORA3ADORA2BADORA1
SCHEMBL6445435 0.75 ADORA2A (0.44) ADORA2ACYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL967156 0.74 ALDH1A1 (0.59) CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1
SCHEMBL4413500 0.73 ALDH1A1 (0.49) ADORA2ACYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL2547225 0.71 ADORA2A (1.00) ADORA2AHSD17B10LMNAADORA3ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
CN-1438890-A Adenosine receptor modulators HOFFMANNLA ROCHE AG F (CH) 2003-08-27 CN disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885CYP1A2 339/4885CYP2C9 992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.